Effect of p53 activation on experimental right ventricular hypertrophy

• Published in: PloS one 2020-06, Vol.15 (6), p.e0234872-e0234872
• Main Authors: Veeroju, Swathi, Mamazhakypov, Argen, Rai, Nabham, Kojonazarov, Baktybek, Nadeau, Valerie, Breuils-Bonnet, Sandra, Li, Ling, Weissmann, Norbert, Rohrbach, Susanne, Provencher, Steve, Bonnet, Sébastien, Seeger, Werner, Schermuly, Ralph, Novoyatleva, Tatyana
• Format: Article
• Language: English
• Subjects: Accumulation; Activation; Anesthesia; Angiogenesis; Animal tissues; Apoptosis; Biology; Biology and Life Sciences; Cardiomyocytes; Development and progression; Drug therapy; Endothelial cells; Excellence; Fatty acids; Fibroblasts; Glucose transporter; Health aspects; Heart; Heart failure; Heart hypertrophy; Heme; Hypertension; Hypertrophy; Hypoxia; Medicine; Medicine and Health Sciences; Metabolism; Mitochondria; Oxygenase; p53 Protein; Physiology; Pulmonary arteries; Pulmonary artery; Pulmonary hypertension; Quinacrine; Research and Analysis Methods; Testing; Tumor proteins; Tumor suppressor genes; Ventricle
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0234872

The leading cause of death in Pulmonary Arterial Hypertension (PAH) is right ventricular (RV) failure. The tumor suppressor p53 has been associated with left ventricular hypertrophy (LVH) and remodeling but its role in RV hypertrophy (RVH) is unclear. The purpose of this study was to determine whether pharmacological activation of p53 by Quinacrine affects RV remodeling and function in the pulmonary artery banding (PAB) model of compensated RVH in mice. The effects of p53 activation on cellular functions were studied in isolated cardiomyocytes, cardiac fibroblasts and endothelial cells (ECs). The expression of p53 was examined both on human RV tissues from patients with compensated and decompensated RVH and in mouse RV tissues early and late after the PAB. As compared to control human RVs, there was no change in p53 expression in compensated RVH, while a marked upregulation was found in decompensated RVH. Similarly, in comparison to SHAM-operated mice, unaltered RV p53 expression 7 days after PAB, was markedly induced 21 days after the PAB. Quinacrine induced p53 accumulation did not further deteriorate RV function at day 7 after PAB. Quinacrine administration did not increase EC death, neither diminished EC number and capillary density in RV tissues. No major impact on the expression of markers of sarcomere organization, fatty acid and mitochondrial metabolism and respiration was noted in Quinacrine-treated PAB mice. p53 accumulation modulated the expression of Heme Oxygenase 1 (HO-1) and Glucose Transporter (Glut1) in mouse RVs and in adult cardiomyocytes. We conclude that early p53 activation in PAB-induced RVH does not cause substantial detrimental effects on right ventricular remodeling and function.